PERK3 Antibody

What is PERK and what cellular functions does it regulate?

PERK, also known as EIF2AK3 (eukaryotic translation initiation factor 2-alpha kinase 3), is a metabolic-stress sensing protein kinase primarily involved in the unfolded protein response (UPR). This 125 kDa transmembrane protein serves several critical functions:

• Phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) in response to various stressors

• Acts as a key effector of the integrated stress response (ISR) to unfolded proteins by recognizing and binding misfolded proteins

• Converts EIF2S1/eIF-2-alpha into a global protein synthesis inhibitor while initiating preferential translation of ISR-specific mRNAs

• Promotes ATF4 and QRICH1-mediated reprogramming through selective translation

• Increases mitochondrial oxidative phosphorylation by promoting ATF4-mediated expression of COX7A2L/SCAF1

• Phosphorylates NFE2L2/NRF2 in response to stress, promoting its release from the BCR(KEAP1) complex

• Controls G1 growth arrest through loss of cyclin-D1 during UPR

What applications are PERK antibodies validated for?

PERK antibodies have been validated for multiple experimental applications across different research contexts. The following table summarizes the validated applications for commercial PERK antibodies:

These applications have been cited in numerous publications, with Western blotting being the most commonly utilized technique (111 publications reported for one antibody) .

What is the difference between antibodies targeting total PERK versus phosphorylated PERK?

The distinction between total PERK and phosphorylated PERK antibodies is critical for experimental design and interpretation:

Total PERK antibodies:

Phosphorylated PERK antibodies:

• Specifically recognize PERK when phosphorylated at specific residues (e.g., Thr980/981)

• Critical for monitoring PERK activation during stress responses

• Provide a direct measure of UPR activation

• May show distinct subcellular localization patterns compared to total PERK

• Require specific sample preparation to preserve phosphorylation status

When designing experiments to study PERK activity, researchers should consider using both antibody types to distinguish between changes in expression versus activation states .

What are the expected molecular weights when detecting PERK via Western blot?

PERK detection by Western blot can yield different molecular weight bands depending on post-translational modifications:

• Calculated molecular weight: 125 kDa

• Observed molecular weight: 140 kDa (most common)

• Alternative molecular weight: 170 kDa (heavily modified forms)

These variations are attributed to post-translational modifications such as glycosylation and phosphorylation . Researchers should note that detection of multiple bands is not necessarily indicative of non-specific binding but may represent different modified forms of PERK . It is advisable to include positive controls such as HEK-293, HepG2, or MCF-7 cell lysates when optimizing Western blot protocols .

What cellular compartments contain PERK and how does this affect antibody selection?

PERK exhibits specific subcellular localization that affects experimental design and antibody selection:

• Primary location: Endoplasmic reticulum (ER) membrane as a single-pass type I membrane protein

• Secondary location: Mitochondria-endoplasmic reticulum contact sites where it interacts with ATAD3A

• Distribution: Ubiquitously expressed with highest levels in secretory tissues

For immunofluorescence studies, researchers should consider:

• Membrane permeabilization protocols to access the ER-localized PERK

• Co-staining with ER markers to confirm localization

• Antigen retrieval methods (TE buffer pH 9.0 is recommended for IHC applications)

Mitochondria are notably protected from PERK-mediated unfolded protein response due to PERK inhibition by ATAD3A at mitochondria-ER contact sites , which represents an important consideration for studies focusing on organelle-specific stress responses.

What sample types have been validated with PERK antibodies?

Commercial PERK antibodies have been validated across diverse sample types:

When working with new sample types, researchers should perform validation experiments including positive and negative controls to confirm antibody specificity .

How can I optimize PERK detection in flow cytometry experiments?

Optimizing flow cytometry for PERK detection requires careful consideration of several experimental parameters:

Protocol optimization:

• Use 0.40 μg antibody per 10^6 cells in a 100 μl suspension for intracellular staining

• Employ a fixation buffer appropriate for preserving intracellular epitopes

• Select a permeabilization buffer compatible with intracellular protein detection

• Include Fc blocking reagent to minimize non-specific binding

Experimental planning considerations:

• Document your hypothesis and what will be measured by flow cytometry

• Consider target location (PERK is primarily intracellular)

• Select appropriate stimulation reagents when studying UPR activation

• Choose compensation beads compatible with your antibody species and isotype

Antibody selection factors:

• Consider antigen density when selecting fluorophore brightness

• Account for relative fluorophore brightness in your panel design

• Match excitation/emission wavelengths to available laser/filter configurations

• Perform antibody titration to determine optimal concentration

For quantitative analysis, researchers should include appropriate controls (unstained, isotype, FMO) and consider using standardized beads for consistent results across experiments .

What fixation and permeabilization protocols are most effective for PERK immunofluorescence studies?

Effective detection of PERK in immunofluorescence applications requires optimization of fixation and permeabilization protocols:

Recommended fixation methods:

• Paraformaldehyde (4%) is commonly used for preserving PERK structure while maintaining cellular architecture

• Methanol fixation may be appropriate for certain epitopes but can disrupt some conformational epitopes

Optimal permeabilization approaches:

• For cell lines (e.g., HEK-293): 0.1-0.5% Triton X-100 or 0.1% Saponin is generally effective

• For tissue sections: More extensive permeabilization may be required to access ER-localized PERK

Critical protocol considerations:

• Dilution range: Use PERK antibodies at 1:50-1:500 dilution for IF applications

• Blocking: Include 1-5% BSA or normal serum from the secondary antibody host species

• Incubation times: Optimal results often require overnight primary antibody incubation at 4°C

• Secondary antibody selection: Choose secondary antibodies with minimal cross-reactivity

Researchers should note that detection of phosphorylated PERK may require phosphatase inhibitors throughout the fixation and staining process to preserve phosphorylation status .

How does antibody format affect experimental design for therapeutic antibody development against PERK?

When developing therapeutic antibodies targeting PERK, researchers must consider multiple factors regarding antibody format and engineering:

scFv to full-length IgG conversion:

• Selected single-chain variable fragments (scFvs) can be sequenced and cloned to generate full-length IgGs

• The pTRIOZ expression vector with three cassettes encoding heavy chain, light chain, and antibiotic selection can be utilized for optimal expression

• Signal sequences should be added at the 5' sequence of both heavy and light chain variable regions

Expression and purification considerations:

• Endotoxin-free plasmid DNA preparation is essential for large-scale expression

• ExpiCHO-S cells enable high transient expression levels of recombinant antibodies

• Purification can be performed via HiTrap MabSelect PrismA column on an ÄKTA pure system

• Additional purification via gel filtration chromatography on Superdex 200 improves homogeneity

Functional characterization:

• Surface Plasmon Resonance (SPR) is effective for measuring functional affinity of anti-PERK IgGs

• Protein-protein docking simulations can predict antibody-antigen interactions

• In-silico immunogenicity assessment using platforms like Epibase can evaluate risk profiles

• Cell-based immunoreactivity assays determine the immunoreactive fraction of conjugated antibodies

The development process should include epitope mapping to confirm antibody binding sites and avoid interfering with critical PERK functions unless therapeutically intended .

How can I validate PERK antibody specificity using knockout/knockdown controls?

Rigorous validation of PERK antibodies requires carefully designed knockout (KO) or knockdown (KD) controls:

Knockout/knockdown validation approaches:

• Multiple publications (at least 4) have reported KO/KD validation for commercial PERK antibodies

• Western blot analysis comparing wild-type to PERK KO/KD samples provides definitive specificity confirmation

• Immunofluorescence staining of KO/KD samples helps visualize background or cross-reactivity issues

Implementation guidelines:

• CRISPR-Cas9 knockout cell lines serve as gold standard negative controls

• siRNA or shRNA knockdown samples can be used when complete knockout is not feasible

• Include both positive (known PERK-expressing) and negative (KO/KD) controls in parallel experiments

• Validate with multiple techniques (WB, IF, flow cytometry) for comprehensive confirmation

Researchers should note that antibody validation using KO/KD controls is particularly critical for novel applications or when studying weakly characterized PERK functions .

What are the methodological considerations for studying PERK's role in the integrated stress response?

Investigating PERK's role in the integrated stress response (ISR) requires specialized experimental approaches:

Stress induction methods:

• ER stress inducers: Tunicamycin, thapsigargin, DTT, or brefeldin A

• Oxidative stress: Hydrogen peroxide, arsenite

• Nutrient deprivation: Amino acid starvation, glucose deprivation

Detection of PERK activation cascade:

• Monitor PERK auto-phosphorylation using phospho-specific antibodies (e.g., phospho-Thr981)

• Track EIF2S1/eIF-2-alpha phosphorylation at Ser51/52 as a direct PERK substrate

• Measure downstream effects such as ATF4 upregulation and selective mRNA translation

• Assess changes in respiratory chain supercomplexes through COX7A2L/SCAF1 expression

Experimental design principles:

• Include time-course analyses to capture the temporal dynamics of PERK activation

• Compare PERK activation with other ISR kinases (GCN2, PKR, HRI) to determine specificity

• Use PERK-specific inhibitors (e.g., GSK2606414) as chemical validation tools

• Consider organelle-specific effects, particularly at mitochondria-ER contact sites

Researchers should note that mitochondria are protected from the PERK-mediated UPR due to PERK inhibition by ATAD3A, which represents an important control point in the integrated stress response .

How do AI methods contribute to therapeutic antibody development against PERK?

Artificial intelligence approaches are increasingly valuable for PERK antibody development:

Structure prediction for antibody-antigen complexes:

• Models such as ABlooper, IgFold, EquiFold, DeepAB, and ABodyBuilder2 can predict antibody structures

• ABodyBuilder2 (part of ImmuneBuilder suite) demonstrates superior performance for HCDR3 loop prediction with RMSD of 2.81 Å

• tFold-Ab computes single chain structure predictions using ProtXLNet followed by multimer conformation prediction

Inverse folding for antibody design:

• Inverse folding models determine sequences that fold into predefined structures, facilitating antibody optimization

• General protein inverse folding models include ESM-IF1, KW-Design, ProRefiner, GraDe_IF, ProteinMPNN, and SeqPredNN

• Antibody-specific inverse folding methods include AntiFold, AbMPNN, IgDesign, and DiscoTope-3.0

• AntiFold is a version of ESM-IF1 fine-tuned specifically on experimental and predicted antibody structures

Experimental validation workflow:

• In silico-designed antibodies require experimental validation through binding affinity measurements (e.g., SPR)

• Immunoreactivity assays determine the percentage of correctly folded and functional antibodies

• Cell-based assays confirm target engagement and functional effects

• Structural analysis (e.g., protein-protein docking) confirms epitope binding as predicted

These computational approaches can significantly accelerate antibody development by reducing experimental iterations and improving initial candidate quality .

What are the considerations for radioisotope labeling of PERK antibodies for imaging applications?

Developing radioisotope-labeled PERK antibodies for imaging applications involves several key considerations:

Antibody conjugation approaches:

• Optimal drug-antibody ratio (DAR) is critical - high DAR (3.87) may impair target binding in vivo compared to lower DAR (1.05)

• Surface plasmon resonance analysis can quantify the decrease in binding affinity after conjugation (nine-fold decrease with DAR 3.87 vs. five-fold with DAR 1.05)

• Immunoreactivity assessment revealed 81% vs. 96% immunoreactive fractions for DAR 3.87 vs. DAR 1.05 respectively

Radiolabeling validation:

• SDS-PAGE and autoradiography can confirm antibody integrity after radiolabeling

• Intact antibody should be visible at 150kDa under non-reducing conditions

• Both heavy and light chains should be visible under reducing conditions

• ELISA assays can verify that radiolabeled antibodies maintain antigen binding compared to unconjugated equivalents

Experimental applications:

• [89Zr]Zr-labeled antibodies can be used for PET imaging in preclinical models and cancer patients

• Small animal PET imaging and post-PET biodistribution measurements provide in vivo validation

• Optimal conjugation methods vary based on radioisotope (e.g., DFO chelator for 89Zr)

These approaches can be adapted for developing imaging agents targeting PERK in contexts where its expression or activation state serves as a biomarker .

How should researchers address data inconsistencies when using different PERK antibody clones?

When encountering data inconsistencies between different PERK antibody clones, researchers should implement a systematic troubleshooting approach:

Source of inconsistencies analysis:

• Epitope differences: Different antibodies may recognize distinct epitopes that are differentially accessible under various conditions

• Sample preparation effects: Various lysis buffers, fixation methods, or antigen retrieval techniques may preferentially expose certain epitopes

• Antibody format variations: Polyclonal versus monoclonal antibodies have inherent specificity and sensitivity differences

• Post-translational modifications: PERK undergoes glycosylation and phosphorylation that can mask epitopes in a context-dependent manner

Resolution strategies:

• Validate with multiple antibodies targeting different PERK epitopes

• Include knockout/knockdown controls for each antibody to establish specificity

• Perform side-by-side comparison using standardized protocols to identify variables affecting detection

• Consider species-specific differences in antibody reactivity and PERK sequence homology

Best practices for reporting:

• Clearly document antibody catalog numbers, lot numbers, and dilutions used

• Specify exact experimental conditions including buffers, incubation times, and temperatures

• Include all controls and validation data when publishing unexpected or contradictory results

• Consider methodological differences when comparing results to published literature

By implementing these approaches, researchers can resolve data inconsistencies and establish more reliable experimental paradigms for PERK detection.

What are the latest methodological advances in studying PERK-dependent signaling pathways?

Recent methodological advances have enhanced our ability to study PERK-dependent signaling pathways:

Advanced detection technologies:

• Proximity ligation assays can detect endogenous PERK interactions with binding partners in situ

• Phospho-proteomic analysis identifies novel PERK substrates beyond the canonical EIF2S1/eIF-2-alpha

• Live-cell imaging with fluorescent reporters enables real-time monitoring of PERK activation dynamics

• Ribosome profiling quantifies translational changes downstream of PERK activation with nucleotide resolution

Organelle-specific approaches:

• Subcellular fractionation combined with immunoblotting can isolate and analyze PERK at specific locations

• Mitochondria-ER contact site isolation techniques enable studying PERK's role at these critical interfaces

• Super-resolution microscopy visualizes PERK distribution at subcellular structures beyond the diffraction limit

Genetic engineering innovations:

• CRISPR-Cas9 engineered cell lines with endogenously tagged PERK allow physiological expression level studies

• Domain-specific mutations help dissect PERK's kinase-dependent and independent functions

• Conditional knockout models enable tissue-specific and temporally controlled PERK ablation

These methodological advances allow researchers to study PERK beyond its canonical role in the unfolded protein response and explore its functions in mitochondrial biology, oxidative stress, and cell cycle regulation .

What are current challenges in developing therapeutic strategies targeting PERK?

Developing therapeutic strategies targeting PERK presents several significant challenges:

Target biology complexities:

• PERK has both pro-survival and pro-apoptotic functions depending on stress duration and intensity

• The kinase plays different roles across cell types, particularly in secretory tissues where it's highly expressed

• PERK activation affects multiple downstream pathways beyond EIF2S1/eIF-2-alpha phosphorylation

Antibody development considerations:

• Transmembrane localization limits accessibility of certain epitopes for antibody binding

• Conformational changes during activation may expose or mask epitopes in an activation-dependent manner

• Species differences in PERK sequences complicate translation from preclinical to clinical studies

Therapeutic targeting strategies:

• In-silico immunogenicity assessment is critical - analysis platforms like Epibase can calculate DRB1 scores to estimate immunogenicity risk

• Optimal drug-antibody ratios significantly impact binding properties and in vivo behavior (DAR of 1.05 showed better performance than 3.87)

• Cell-based immunoreactivity assays are essential to determine the percentage of functional antibody after modification

• Structure-guided epitope selection can maximize therapeutic effects while minimizing on-target toxicities

These challenges highlight the need for comprehensive preclinical validation using multiple approaches before advancing PERK-targeted therapeutics to clinical testing .